New Insight Wealth Advisors boosted its holdings in Pfizer Inc. (NYSE:PFE - Free Report) by 23.3% during the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 167,834 shares of the biopharmaceutical company's stock after buying an additional 31,696 shares during the quarter. Pfizer makes up 1.7% of New Insight Wealth Advisors' holdings, making the stock its 17th biggest holding. New Insight Wealth Advisors' holdings in Pfizer were worth $4,068,000 as of its most recent SEC filing.
Several other institutional investors have also recently bought and sold shares of PFE. GKV Capital Management Co. Inc. bought a new stake in shares of Pfizer during the first quarter worth $27,000. North Capital Inc. acquired a new stake in shares of Pfizer during the 1st quarter valued at $28,000. Bayforest Capital Ltd bought a new stake in Pfizer during the 1st quarter worth $28,000. Horizon Financial Services LLC acquired a new position in Pfizer in the 1st quarter worth about $35,000. Finally, WPG Advisers LLC bought a new position in Pfizer in the first quarter valued at about $35,000. Institutional investors and hedge funds own 68.36% of the company's stock.
Wall Street Analysts Forecast Growth
Several research analysts have recently issued reports on PFE shares. Citigroup upped their price objective on Pfizer from $25.00 to $26.00 and gave the company a "neutral" rating in a research note on Wednesday, August 6th. Wall Street Zen upgraded shares of Pfizer from a "hold" rating to a "buy" rating in a research report on Saturday, September 20th. Bank of America raised their price target on shares of Pfizer from $27.00 to $28.00 and gave the company a "neutral" rating in a research note on Wednesday, August 6th. Berenberg Bank reduced their price objective on shares of Pfizer from $28.00 to $25.00 and set a "hold" rating on the stock in a research note on Thursday, May 29th. Finally, Morgan Stanley raised their target price on Pfizer from $32.00 to $33.00 and gave the stock an "equal weight" rating in a research report on Wednesday, August 6th. Two research analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating, eleven have given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, Pfizer presently has a consensus rating of "Hold" and an average target price of $28.12.
Read Our Latest Analysis on Pfizer
Pfizer Stock Performance
Shares of Pfizer stock opened at $23.61 on Friday. The business has a 50-day moving average price of $24.57 and a two-hundred day moving average price of $24.16. Pfizer Inc. has a 1-year low of $20.92 and a 1-year high of $30.43. The company has a current ratio of 1.16, a quick ratio of 0.85 and a debt-to-equity ratio of 0.65. The company has a market cap of $134.25 billion, a P/E ratio of 12.56, a PEG ratio of 0.78 and a beta of 0.55.
Pfizer (NYSE:PFE - Get Free Report) last announced its earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 EPS for the quarter, beating the consensus estimate of $0.58 by $0.20. The company had revenue of $14.65 billion for the quarter, compared to analyst estimates of $13.43 billion. Pfizer had a return on equity of 21.42% and a net margin of 16.84%.The firm's revenue for the quarter was up 10.3% compared to the same quarter last year. During the same quarter in the prior year, the company earned $0.60 EPS. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. As a group, analysts anticipate that Pfizer Inc. will post 2.95 EPS for the current year.
Pfizer Profile
(
Free Report)
Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Pfizer, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pfizer wasn't on the list.
While Pfizer currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
